Tuesday, January 17, 2012

2010 Collaborative Grant - An Effective Means of Utilizing Limited Funds

Collaborative Grant to University of Washington

Although this is the news about a jointly-funded project in 2010-2012, it is out hope that more collaboration between funding groups will happen in the coming years. It is an effective way to stimulate new projects, increase awareness of a condition and maximize our funds. Here is one example of how groups can work together effectively.

Collaborative Grant to University of Washington Researcher to
Speed Therapy Development for FSH Dystrophy

TUCSON, Ariz., and KIRKLAND, Wash., April 5, 2010 ─ The Muscular Dystrophy Association (MDA), headquartered in Tucson, Ariz., and Friends of FSH Research (FFSHR), based in Kirkland, Wash., today jointly awarded a two-year, $200,000 grant to Joel Chamberlain, research assistant professor of medical genetics at the University of Washington. The grant, equally funded by the two organizations, will enable the laboratory led by Dr. Chamberlain to study RNA interference as an investigative and therapeutic tool forfacioscapulohumeral muscular dystrophy.
“We’re delighted to be funding this cutting-edge research aimed at finding a therapy for FSH dystrophy,” says Valerie Cwik, MDA Executive Vice President – Research and Medical Director. “Not only might this project identify the precise molecular cause of FSHD — which has eluded us — but it could also rapidly suggest a viable therapeutic approach to the disease.”
Last fall, MDA and FFSHR teamed up to issue a worldwide request for applications (RFA) for projects targeting the identification, prioritization and/or validation of molecular targets for potential therapies for FSH dystrophy. The goal is to stimulate a new wave of innovative FSH dystrophy research to help people affected by the progressive neuromuscular disease, which can cause weakness in the upper body, lower leg, hip or abdominal muscles; hearing loss; and retinal eyesight, heart or respiratory muscle abnormalities.
“Our RFA is proving to be a strong catalyst for vital research,” notes Terry Colella, FFSHR President. “We’re creating new momentum in the field of FSH dystrophy research and Dr. Chamberlain’s work should quickly bring us closer to a much needed therapy or cure.”
The Chamberlain project will focus on the recently discovered biological process, called RNA interference (RNAi), that cells normally use to fine-tune the levels of proteins that carry out body functions. “We’re developing ways to harness the potential for directed RNAi to turn off production of specific proteins in muscle that are thought to cause FSH dystrophy,” explains Chamberlain. “Thanks to funding from MDA and Friends of FSH Research, we soon should be ready to target promising therapies to attack this disease.”
A second notable FSH research project also was identified as a result of the joint RFA distributed by MDA and FFSH Research. That meritorious project, led by Silvere van der Maarel at Leiden University Medical Center in the Netherlands, is being funded by MDA and will use a slightly different approach (antisense oligonucleotides) to develop potential treatments for FSH dystrophy.
Leveraging Prior Insights
The exciting new initiatives will benefit from decades of FSH dystrophy research seeking the elusive genetic cause of FSH dystrophy and defining the varied course of the disease. Notable advances made by investigators benefiting from MDA’s more than $16 million investment in FSH dystrophy research since 1987 include:
  • mapping the genetic mutation causing FSH dystrophy to a small region near one end of chromosome 4;
  • determining that many genes are incorrectly regulated in muscles affected by FSH dystrophy;
  • finding that abnormal DNA in the disease-associated region of chromosome 4 inappropriately activates gene expression in FSH dystrophy; and
  • discovering that an unusual looping of chromosome 4, marked by an abnormally short D4Z4 region, has widespread consequences for gene regulation in FSH dystrophy.
About Friends of FSH Research
Friends of FSH Research was formed by the family and friends of Brian Colella, who was diagnosed with facioscapulohumeral dystrophy, or FSHD, in 2004. As an independent, 501(c)(3) nonprofit tax-exempt organization, the organization’s goal is to raise money to help fund researchers trying to decode the genetic mysteries of FSHD so that a treatment or cure can be developed.
Friends of FSH Research was created because there is a need for additional funds for FSHD research. To stimulate new research and support for current researchers in this field, it was essential that a fundraising organization be founded. Friends of FSH Research is excited by the opportunity to help those affected by this disabling condition by funding scientists researching FSHD, and we feel very lucky to have established a partnership with the Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center at the University of Washington.
About MDA
MDA is the nonprofit health agency dedicated to curing muscular dystrophy, ALS and related diseases by funding worldwide research. The Association, which maintains a network of more than 200 hospital-affiliated clinics nationwide, also provides comprehensive health care and support services, advocacy and education.
Founded in 1950, MDA is the nation’s largest nongovernmental funder of research seeking treatments and cures for more than 40 neuromuscular diseases, including muscular dystrophy, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), Charcot-Marie-Tooth disease (CMT), and Friedreich’s ataxia (FA).
The first nonprofit organization to be recognized with a Lifetime Achievement Award from the American Medical Association (“for significant and lasting contributions to the health and welfare of humanity”), MDA’s annual investment in research exceeds $40 million.
Thanks to decades of generous contributions from caring individuals, plus outstanding support received from local, regional and national sponsors, MDA is credited for its role in building the entire field of neuromuscular disease research, while simultaneously nurturing clinical care to significantly improve both quality and length of life for those affected by neuromuscular diseases.

No comments: